Attributes | Values |
---|
rdf:type
| |
description
| - videnskabelig artikel (da)
- article científic (ca)
- articolo scientifico (it)
- artigo científico (pt)
- bilimsel makale (tr)
- vedecký článok (sk)
- vetenskaplig artikel (sv)
- vědecký článek (cs)
- wetenschappelijk artikel (nl)
- wissenschaftlicher Artikel (de)
- научни чланак (sr)
- bài báo khoa học (vi)
- article scientifique (fr)
- artículu científicu espublizáu en 2014 (ast)
- наукова стаття, опублікована в березні 2014 (uk)
- scientific article published on 27 March 2014 (en)
- مقالة علمية نشرت في 27 مارس 2014 (ar)
|
publication date
| |
publication date
| |
language of work or name
| |
language of work or name
| |
author name string
| |
author name string
| - Fabio Vecchio
- Mariacarmela Santarpia
- Tommaso De Pas
- Francesca Toffalorio
- Gianluca Spitaleri
- Massimo Barberis
- Caterina Fumagalli
- Cristina Noberasco
- Chiara Catania
- Laura Dal Zotto
- Monique Zangarini
- Tullia Diena
- Veronica Brunelli
|
rdfs:label
| - Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (en)
- Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (nl)
- Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (ast)
|
skos:prefLabel
| - Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (en)
- Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (nl)
- Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (ast)
|
name
| - Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (en)
- Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (nl)
- Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets. (ast)
|
author
| |
author
| |
title
| |
title
| - Phase ib of sorafenib in combination with everolimus in patients with advanced solid tumors, selected on the basis of molecular targets (en)
|
page(s)
| |
page(s)
| |
instance of
| |
instance of
| |
PubMed ID
| |
PubMed ID
| |
PubMed ID
| |
published in
| |
published in
| |
issue
| |
volume
| |
issue
| |
volume
| |
number of pages
| |
number of pages
| |
DOI
| |
DOI
| |
DOI
| - 10.1634/THEONCOLOGIST.2013-0335
|
ResearchGate publication ID
| |
ResearchGate publication ID
| |
PMCID
| |
PMCID
| |
is about
of | |
is cites work
of | |
is cites work
of | |